reports
Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Re...
Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021 -- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 -- -- Total prescriptions of GOCOVRI of approximately 8,165 for fourth quarter 2020 and approximately 31,070* for full year 2020 -- EMERYVILLE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated...
Adamas to Present at Upcoming ICR Conference
Adamas to Present at Upcoming ICR Conference EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021. The fireside chat will be webcast live on January 14, 2021 at 11:30 a.m. Eastern Time on the investor relations section of the Adamas website at . Th...
Adamas Completes Acquisition of OSMOLEX ER®
Adamas Completes Acquisition of OSMOLEX ER® Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition EMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc and completes the acquisition of the global rights to OSMOLEX ER®. As previously disc...
Adamas to Present at Upcoming H.C. Wainwright Conference
Adamas to Present at Upcoming H.C. Wainwright Conference EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021. A replay of the pre-recorded fireside chat will be available beginning January 11, 2021 in the in...
Adamas Announces New Employment Inducement Grant
Adamas Announces New Employment Inducement Grant EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company’s common stock, at a per share exercise price of $4.88, the closing trading price on December 7, and restricted stock units to acquire 14,250 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuan...
Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with...
Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners Amended terms will provide added flexibility to help drive the growth of the Company EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has entered into an agreement to amend certain key terms of its Royalty-Backed Loan agreement (“Royalty-Backed Loan”) with HealthCare Royalty Partners (“...
Adamas Announces Agreement to Settle Patent Litigation with Osmotica
Adamas Announces Agreement to Settle Patent Litigation with Osmotica As part of this agreement Adamas will acquire the global rights to OSMOLEX ER® EMERYVILLE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed an agreement to settle its ongoing patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc. As a result of this agreement, both parti...
Adamas to Present at Upcoming Evercore ISI Conference
Adamas to Present at Upcoming Evercore ISI Conference EMERYVILLE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1st at 11:45 am Eastern Time (8:45 am Pacific). The presentation will be webcast from the investor relations section of the Ad...
Adamas announces changes to its Board of Directors with the appointmen...
Adamas announces changes to its Board of Directors with the appointment of Spyros Papapetropoulos and the retirement of Ivan Lieberburg EMERYVILLE, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scie...
Adamas to Present at Upcoming Piper Sandler Conference
Adamas to Present at Upcoming Piper Sandler Conference EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held December 1-3, 2020. A replay of the pre-recorded fireside chat will be available beginning November 23, 2020 in t...
Adamas Announces New Employment Inducement Grant
Adamas Announces New Employment Inducement Grant EMERYVILLE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 45,000 shares of the company’s common stock, at a per share exercise price of $3.45, the closing trading price on November 6, and restricted stock units to acquire 22,500 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursu...
Adamas Reports Third Quarter 2020 Financial Results
Adamas Reports Third Quarter 2020 Financial Results Third quarter 2020 total revenues of $20.2 million, a 45% increase over third quarter 2019 Third quarter 2020 GOCOVRI® product sales of $19.0 million, a 36% increase over third quarter 2019 Total paid prescriptions of 7,930, a 19% increase over third quarter 2019 EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today re...
Adamas announces settlement agreement of previously disclosed class ac...
Adamas announces settlement agreement of previously disclosed class action litigation EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has signed a Memorandum of Understanding to settle one of the previously disclosed securities class-action lawsuits, Plymouth v. Adamas Pharmaceuticals, Inc., et al., Case No. RG19018715, pending in the California Superior Court for the County of Alamed...
Adamas to Announce Third Quarter 2020 Financial Results and Host Confe...
Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020 EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. Investor Conference Call and Webcast The conference call can be accessed by dialing (844) 215...
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinsonâ...
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress EMERYVILLE, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine) extended release capsules (ADS-5102) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy ...
- Dave Nicoski
- Ross LaDuke
BSX BOSTON SCIENTIFIC CORPORATION
SIX SIX FLAGS ENTERTAINMENT CORPORATION
DAL DELTA AIR LINES INC.
VHI VALHI INC.
TLYS TILLYS
1AMQ TEXTAINER GROUP HOLDINGS LIMITED
TDS TELEPHONE AND DATA SYSTEMS INC.
SPNE SEASPINE HOLDINGS CORP.
RNET RIGNET
RGA REINSURANCE GROUP OF AMERICA INCORPORATED
PSA PUBLIC STORAGE
OEC ORION ENGINEERED CARBONS SA
NVCR NOVOCURE LTD.
MOS MOSAIC COMPANY
MGPI MGP INGREDIENTS INC.
MDT MEDTRONIC PLC
GPC GENUINE PARTS COMPANY
FOSL FOSSIL GROUP INC.
EXPE EXPEDIA GROUP INC.
EMN EASTMAN CHEMICAL COMPANY
CE CELANESE CORPORATION
ATRA ATARA BIOTHERAPEUTICS INC
ANF ABERCROMBIE & FITCH CO. CLASS A
AEO AMERICAN EAGLE OUTFITTERS INC.
ADMS ADAMAS PHARMACEUTICALS INC.
G2O GOLAR LNG LIMITED
DLTH DULUTH HOLDINGS INC. CLASS B
DRI DARDEN RESTAURANTS INC.
LYV LIVE NATION ENTERTAINMENT INC.
VRA VERA BRADLEY INC.
WMB WILLIAMS COMPANIES INC.
USM UNITED STATES CELLULAR CORP
AFI ARMSTRONG FLOORING INC.
DFIN DONNELLEY FINANCIAL SOLUTIONS INC.
ARCH ARCH RESOURCES INC. CLASS A
FTV FORTIVE CORP.
WRK WESTROCK COMPANY
GM GENERAL MOTORS COMPANY
LBRT LIBERTY OILFIELD SERVICE
ST SENSATA TECHNOLOGIES HOLDING PLC
SPB SPECTRUM BRANDS HOLDINGS INC.
NXGN NEXTGEN HEALTHCARE INC.
MEC MAYVILLE ENGINEERING
KTB KONTOOR BRANDS
ALRS ALERUS FINANCIAL CORP.
FBRX FORTE BIOSCIENCES INC
VTOL BRISTOW GROUP
INC.
Adamas to Present at Upcoming HC Wainwright Conference
Adamas to Present at Upcoming HC Wainwright Conference EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time (9:30 am Pacific). The presentation will be webcast live from the investor relati...
Adamas Appoints Anna Richo to Board of Directors
Adamas Appoints Anna Richo to Board of Directors EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, Inc., to its Board of Directors. She will also serve on the Audit Committee. Ms. Richo brings over 30 years of leadership experience managing legal and compliance functions with...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.